Aggrey Mweemba

Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa

Nicholas I. Paton, Cissy Kityo, Anne Hoppé et al. · New England Journal of Medicine · 2014 · 201 citations · Full text

Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey

Lloyd Mulenga, Jonas Z. Hines, Sombo Fwoloshi et al. · The Lancet Global Health · 2021 · 163 citations · Full text

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

Nicholas I. Paton, Cissy Kityo, Immaculate Nankya et al. · The Lancet HIV · 2017 · 79 citations · Full text

Effect of Baseline Renal Function on Tenofovir-Containing Antiretroviral Therapy Outcomes in Zambia

Lloyd Mulenga, Patrick Musonda, Albert Mwango et al. · Clinical Infectious Diseases · 2014 · 65 citations · Full text

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

James Hakim, Cissy Kityo, Anne Hoppé et al. · The Lancet Infectious Diseases · 2017 · 41 citations · Full text